Kyntra Bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thane Wettig
- Full Time Employees
- 225
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 350 Bay Street San Francisco CA United States of America 94133
- IPO Date
- Nov 14, 2014
- CIK
- 0000921299
- Website
- kyntrabio.com
- Similar Companies
- Business
- Kyntra Bio, Inc. engages in research, development, and commercialization of biopharmaceutical therapeutics focused on hypoxia-inducible factor biology and connective tissue growth factors to address serious unmet medical needs. The company discovers, develops, manufactures, and markets therapeutics addressing anemia, fibrotic diseases, cancer, and related conditions, with an emphasis on hypoxia pathways and tissue remodeling. Primary products and services include small molecule and biologic therapeutics targeting hypoxia-inducible factors, prolyl hydroxylase inhibitors, and candidates addressing anemia of chronic disease and myelodysplastic syndromes, alongside companion diagnostics and research collaborations. Geographically, Kyntra Bio operates across North America, Europe, and Asia-Pacific regions, with headquarters in San Francisco, California, United States, and a workforce focused on early-stage discovery through late-stage development, regulatory strategy, and commercialization support. Since its founding in 1993, the company maintains subsidiary and partner relationships to advance clinical programs, manufacturing capabilities, and strategic alliances with biopharmaceutical and biotechnology entities. Recent developments include strategic partnerships and collaborations, ongoing or recently completed funding rounds or acquisitions, and new product launches or service offerings that expand its therapy portfolio and research capabilities. The company’s business segments span discovery, preclinical and clinical development, regulatory affairs, medical affairs, manufacturing, and commercial operations, serving pharmaceutical and biotechnology customers, healthcare providers, and patients seeking innovative treatments. Foundationally, Kyntra Bio emphasizes a pipeline driven by hypoxia pathway modulation and connective tissue growth factor biology, with ongoing efforts to broaden its global reach through expanded geographic access and strategic alliances. This description reflects current publicly available information on Kyntra Bio, Inc. and its corporate activities.
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Kyntra Bio to Report First Quarter 2026 Financial Results
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript